UNCY, US90466Y2028

Class action sets November 2 deadline for Unicycive Therapeutics stock

Published on 10/21/2026 at 00:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Levi & Korsinsky issued a lawsuit alert on October 19, 2026. Unicycive Therapeutics stock fell 39.1 percent on June 30 after the FDA response.

Regulatory and legal milestones

A shareholder lawsuit alert cited a 39.1 percent single-day decline on June 30, 2026.
Cash, cash equivalents and marketable securities totaled USD 61.4 million on June 30, 2026.
Unicycive Therapeutics stock was last quoted at USD 3.80 at 4:00 p.m. ET on Nasdaq on October 20, 2026.

UNCY, US90466Y2028, Illustration mit AI erstellt.

Unicycive Therapeutics (ISIN US90466Y2028) faces a November 2, 2026 deadline for lead plaintiff motions after a shareholder lawsuit was highlighted by GlobeNewswire on October 19, 2026. The allegations center on manufacturing oversight and the regulatory path for oxylanthanum carbonate.

Three milestones shape the case

On June 30, 2026, Unicycive disclosed a second Complete Response Letter from the FDA, while the shareholder alert said the stock fell 39.1 percent to USD 4.69. The source attributed the decline to the repeated manufacturing deficiencies cited in the regulatory response.

On September 29, 2026, the company resubmitted its New Drug Application for oxylanthanum carbonate with 12 months of stability data from a new manufacturing vendor, according to FinanzNachrichten. The release also said cash, cash equivalents and marketable securities totaled USD 61.4 million as of June 30, 2026.

On October 19, 2026, GlobeNewswire reported that motions to become lead plaintiff must be filed by November 2, 2026. The alert described the allegations as claims, not judicial findings.

What does the lawsuit mean for cash?

The financial cushion is a key counterweight to the regulatory dispute. The September 29 release said the USD 61.4 million cash position supported preparation for a potential OLC launch and an expected runway into the second half of 2027, according to FinanzNachrichten. That runway gives the company time to pursue the revised regulatory route, but it does not resolve the manufacturing issue described in the lawsuit allegations.

The next legal date

November 2, 2026 is the next substantiated date in the case and marks the deadline for lead plaintiff motions. The companys September 29 resubmission remains the latest documented regulatory milestone in the source record.

Nasdaq quote and valuation

Unicycive Therapeutics was last quoted at USD 3.80 on Nasdaq on October 20, 2026 at 4:00 p.m. ET. Its market capitalization was USD 104.1 million, and its 52-week range was USD 3.35 to USD 8.74, as of the same date.